NYT: Pfizer testifies before British Parliament on AstraZeneca deal
LONDON — Pfizer testified before British Parliament Tuesday regarding its proposed offer to acquire AstraZeneca, the New York Times reported. According to the report, British lawmakers challenged Ian Read, Pfizer CEO, on the company’s commitment to keep jobs in the United Kingdom.
In response, Pfizer committed to keep at least 20% of its combined research-and-development teams in Britain and would follow through on completing a center in Cambridge, England that AstraZeneca has started. Beyond that, Pfizer could make no guarantees, Read said.
The report also suggested Pfizer may be willing to raise the stakes with a higher offer in its proposed acquisition of AstraZeneca, asking AstraZeneca executives to help draft an acceptable deal.
FDA accepts Teva’s sNDA for pediatric QNASL
JERUSALEM — Teva Pharmaeceuticals on Tuesday announced that the Food and Drug Administration accepted the company’s supplemental new drug application for a lower dose QNASL (beclomethasone dipropionate) nasal aerosol, which is used for the treatment of seasonal and perennial allergic rhinitis in children ages 4 years to 11 years.
QNASL, a waterless intranasal corticosteroid spray, is currently available to treat patients 12 years of age and older who show symptoms of seasonal allergic rhinitis and perennial allergic rhinitis, the company notes.
“We are very pleased the FDA has accepted for review the sNDA for QNASL. If the FDA approves the new indication for QNASL, it will become the first waterless HFA nasal allergy treatment approved for patients as young as 4 years of age,” said Tushar Shah, M.D., SVP at Teva Global Respiratory Research and Development. “The low-dose formulation demonstrates our commitment to the development of innovative treatment options for all patients with respiratory conditions, including nasal allergies.”
Report: Mainstream pharmacy won’t dispense medical marijuana
NEW YORK — Sales of medical marijuana will remain within a burgeoning specialty channel without competition from traditional retail players like CVS Caremark, Rite Aid or Walgreens, Bloomberg Businessweek reported Tuesday.
Though more than 21 states have legalized marijuana for medical use, according to the report, pharmacy operators would violate the registrations with the Drug Enforcement Agency that enables them to dispense controlled substances.
At the federal level, marijuana is classified as a Schedule I drug, making it illegal to prescribe or dispense, the report noted.